Evidence map›Paper›PMID 39170968›Full record

ArticleNanoscale advances2024

Multiplexed immunolabelling of cancer using bioconjugated plasmonic gold-silver alloy nanoparticles.

Cécile Darviot, Bryan Gosselin, Flavie Martin, Sergiy Patskovsky, Ivan Jabin, Gilles Bruylants, Dominique Trudel, Michel Meunier

Abstract read
In one paragraph

Article in Nanoscale advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Cécile DarviotPolytechnique Montréal Montréal Canada michel.meunier@polymtl.ca.ORCID https://orcid.org/0000-0003-4052-3079
Bryan GosselinUniversité Libre de Bruxelles, LCO Bruxelles Belgium.
Flavie MartinPolytechnique Montréal Montréal Canada michel.meunier@polymtl.ca.
Sergiy PatskovskyPolytechnique Montréal Montréal Canada michel.meunier@polymtl.ca.ORCID https://orcid.org/0000-0001-7175-481X
Ivan JabinUniversité Libre de Bruxelles, LCO Bruxelles Belgium.ORCID https://orcid.org/0000-0003-2493-2497
Gilles BruylantsUniversité Libre de Bruxelles, EMNS Bruxelles Belgium.ORCID https://orcid.org/0000-0003-1752-5826
Dominique TrudelCentre Hospitalier de l'Université de Montréal Montréal Canada.
Michel MeunierPolytechnique Montréal Montréal Canada michel.meunier@polymtl.ca.ORCID https://orcid.org/0000-0002-2398-5602

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Reliable protein detection methods are vital for advancing biological research and medical diagnostics. While immunohistochemistry and immunofluorescence are commonly employed, their limitations underscore the necessity for alternative approaches. This study introduces immunoplasmonic labelling, utilizing plasmonic nanoparticles (NPs), specifically designed gold and gold-silver alloy NPs (Au:Ag NPs), for multiplexed and quantitative protein detection. These NPs, when coupled with antibodies targeting proteins of interest, enable accurate counting and evaluation of protein expression levels while overcoming issues such as autofluorescence. In this study, we compare two nanoparticle functionalization strategies-one coating based on thiolated PEG and one coating based on calix[4]arenes-on gold and gold-silver alloy nanoparticles of varying sizes. Overall results tend to demonstrate a greater versatility for the calix[4]arene-based coating. With this coating and using the classical EDC/sulfo-NHS cross-linking procedure, we also demonstrate the successful multiplexed immunolabelling of Her2, CD44, and EpCAM in breast cancer cell lines (SK-BR-3 and MDA-MB-231). Furthermore, we introduce a user-friendly software for automatic NP detection and classification by colour, providing a promising proof-of-concept for the practical application of immunoplasmonic techniques in the quantitative analysis of biopsies in the clinical setting.

Identifiers

PMID39170968
PMCPMC11334976

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.